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Posttransplant lymphoproliferative disorders (PTLD) are increasingly recognized as a life threatening complication of transplantation. 
Complicating range from polyclonal hyperplasia of the 
lymphoid system to monoclonal non-Hodgkin lym-
phoma.1-3 PTLD is associated with a high rate of graft 
loss and patient mortality, due to its devastating, unpre-
dictable and often treatment-irresponsive nature of the 
disease.4,5 The main pathogenesis of the disease arises 
from defects that usually occur in T-cell regulation pro-
cesses leading to uncontrolled proliferation of B or T 
lymphocytes, generally in response to Epstein-Barr vi-
rus (EBV), or some other viral infections.6,7 
Compared to lymphomas developing in the normal 
population, PTLD usually represent a more unfavor-
able histopathological presentation, a more aggressive 
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BaCKgROunD anD OBjECtIVES: Due to the limited incidence of posttransplant lymphoproliferative dis-
orders (PtLD) in pediatric liver graft recipients, there is a scarcity of data  on the characteristics of the disease 
in this population. We aimed to analyze the special features and behavior of PtLD arising after pediatric liver 
transplantation. 
DESIgn: a comprehensive search of the literature was conducted for the available data on PtLD in pediatric 
liver recipients pediatric PtLD through a search of Pubmed and Google scholar using appropriate terms. 
mEthODS:  We sought data on liver recipients younger than 18 years of age at the time of transplantation. from 
51 reports, 43 fulfilled the inclusion criteria. overall 250 cases of PtLD (212 pediatric PtLD) were found from 
43 reports. Data on pediatric patients was compared to adults.
RESuLtS: Pediatric PtLD lesions were more likely of the polymorphic type (P=.004) and polyclonal (when age 
cut-off was defined at 12 years; P=.023). remission rates, metastasis frequency and organ involvements were not 
different between the groups (P>.1 for all). survival analysis showed no disparity between pediatric PtLD and 
adult patients (P>.1); but when data was reanalyzed for patients surviving at least 4 months post diagnosis, the 
log rank test showed that pediatric patients have a superior outcome compared to adults (P=.045).
COnCLuSIOnS: Pediatric liver recipients developing PtLD have relatively better disease presentation and be-
havior than that in adults. stomach involvement was also more frequently seen in patients younger than 12 years, 
and should be more intensively evaluated. future studies with a prospective approach and larger population size 
are needed for confirming our results.
clinical course, lesser responsiveness to conventional 
interventions, and a poorer outcome.8 These unwanted 
features of PTLD become more prominent in the pe-
diatric transplant population, where data scarcity exists 
on the clinical course and safety and effectiveness of 
conventional therapies in managing the disease. Due to 
the overall higher number of adults undergoing organ 
transplantation, most of the available data in the cur-
rent literature address PTLD arising in adult patients, 
and available data in the pediatric context are limited.
PTLD has been shown the most common tumor 
in solid organ transplanted children, with an overall 
incidence rate of 5% to 15% in different series whose 
share in the frequency of post-transplant malignancies 
is over 50% of all tumors.9,10 The reported rate of mor-
tality for this population is also extremely high (up to 
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60%) although reports with lower mortality rates also 
exist.9,11,12 Some of the recommended reasons for these 
elevated risks in pediatric transplant context are young 
age, transplant time, EBV seronegativity, and long-term 
immunosuppression. 
As mentioned, most of the data available in the 
literature on PTLD have been derived from adult 
populations, and data on children are mostly from 
single- or multicenter reports of small series. We con-
ducted a very comprehensive and thorough search to 
find all individual pediatric cases in series whose data 
were presented by authors who tried to standardize 
their data and acccumulate their data to find potential 
clinical and  histopathological features of lesions, and 
prognoses specifically associated with PTLD in this 
patient population.
mEthODS
Pubmed and Google Scholar were comprehensively 
searched for reports on lymphoproliferative disorders 
developing in liver transplanted children. Keywords 
used included “lymphoproliferative disorders + trans-
plantation + liver + pediatric” “lymphoproliferative 
disorders + liver + transplantation + children” “lym-
phoproliferative disorder + liver + transplantation + 
childhood” “lymphoproliferative disorders + liver + 
transplantation + young”. The search was empowered 
by following the citations of each article, and our previ-
ous searches on liver transplantation. Wherever the full 
text of the articles were not obtainable, we contacted 
correspondent authors of each article through their 
email addresses requesting the article. Then we includ-
ed reports in which data for each patient was presented 
individually, into the database. Lymphoproliferative dis-
orders occurring after liver transplantation in children 
(pediatric PTLD) were considered as our case group 
and adult liver transplant recipients developing PTLD 
were included as controls. Controls were selected from 
the same studies as the case group. Pediatric patients 
were defined as younger than 18 years of age; patients 
18 years or older were considered adults. A question-
naire was developed to collect data from the included 
series. Data from 43 previously published studies were 
included in the analysis.11, 13-54 
Due to the inconsistencies in data presentations as 
well as approaches used in the studies included into 
this survey, it was not possible to get all data we needed 
from all the included patients. So, we tried to standard-
ize data of different studies by implementing new defi-
nition criteria. Disseminated lymphoma was diagnosed 
when it was declared by the authors or at least three 
different organs (Different lymph node areas were ex-
cluded from analysis due to lack of knowledge categori-
zation) were involved by PTLD, reported in 26 (23.9%; 
141 unreported) patients. Multiorgan involvement, de-
fined as involvement of more than a unique organ as 
well as more than one lymphatic region, was available in 
80 (53%; 99 unreported) patients. 
Response to treatment termed “remission” was de-
fined as any favorable change in the cancer measures as 
well as patients’ clinical condition; we also developed 
new criteria for defining remission rates for the study 
population; while remission episode was presumed 
available when patients were alive after their 24th 
month of PTLD diagnosis (since, reported cases hav-
ing this criterion had at least one confirmed remission 
episode) and no remission was defined when a patient 
died within the first month post-PTLD diagnosis (be-
cause among reported cases there were no patients dy-
ing at the first post-transplant month and reported to 
have any remission episodes).  
Software used for data analyses was SPSS v.13.0. 
Statistical differences between patient subgroups were 
performed by using chi-square and the Fisher exact 
test for proportions and the t test for continuous data. 
Survival analysis was done with life tables and Kaplan-
Meier methods and log-rank test. All statistical tests 
were performed at the .05 significance level.  
RESuLtS
Data on 250 liver transplant recipients who devel-
oped lymphoproliferative disorders were enrolled into 
analysis, of which 212 (84.8%) were children ≤18 
years. Seventy-three (51%) of the study participants 
were male and 70 (50%) were female (107 unreport-
ed). Mean age and standard deviation at diagnosis of 
PTLD was 9.9 (15.7) years (Table 1). The mean (SD) 
interval between transplantation and the diagnosis of 
PTLD was 28.7 (35.1) months whereas follow-up 
time after diagnosis of PTLD was 34.5 (39.1) months. 
Two hundred and twelve (84.8%) patients had under-
gone liver transplantation at a pediatric age, while the 
remaining 38 (15.2%) recipients were adults. Patient 
EBV infection status was documented in 114 (45.6%) 
patients of whom 95 (83.3%) were positive. According 
to remission criteria, 120 (48%) patients represented 
data on remission of whom 96 (80%) had at least one 
remission episode, irrespective of their future disease 
behavior. Overall mortality was 56 (35.4% of the re-
ported cases; 92 unreported) patients; 35 (72.9%) of 
the mortality was due to PTLD disease (8 (14.3%) 
unreported data).
Chi square tests showed that pediatric PTLD le-
sions were significantly more frequent of early histo-
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pathological features (P=.037). When age cut-off point 
was decreased to 12 years, pediatric PTLD lesions were 
more likely to be both polymorphic (P=.004) and poly-
clonal (P=.023). Pediatric PTLD were comparable to 
their adult counterparts lesions cell types (P=.303), rate 
of EBV infection (P=.609), multiorgan involvement 
(according to the defined criteria; P=.518), dissemi-
nated PTLD (according to the defined criteria; P=.79), 
and in representing any remission episodes in their dis-
ease course (P=.604) (Table 1). 
Table 2 summarizes different organ involvements 
by PTLD in pediatric PTLD patients and compares 
them with the adult group. No priority for organ com-
plication by PTLD was detected for pediatric patients. 
When age cut-off was defined at 12 years, pediatric 
patients were significantly more likely to complicate 
the stomach (P=.035). Time from transplantation to 
PTLD development was also comparable between the 
study groups (P=.531).
At the last follow, 56 (35.4%) patients were dead. 
Survival analysis showed no significant difference in 
the outcome of PTLD in pediatric versus adult pa-
tients (P=.244; Figure 1). However, after the very ear-
ly post transplantation time, the survival curve of pe-
diatric PTLD goes upward, indicating better survival. 
Thus, we reanalyzed data censoring mortalities within 
the early months, and increased the time interval step 
by step. We found that after censoring events before 
the 4th post diagnosis month, the survival difference 
between pediatric PTLD and adult PTLD liver recip-
ients reached to the significance level (P=.041; Figure 
2). One and 5-year survival rates for the pediatric 
PTLD patients were 76% and 64%, respectively; com-
pared to 73% and 57%, respectively, for the controls.
Study participants were categorized based on the 
time of PTLD development (versus time at transplan-
Table 1. Characteristics of liver transplant recipients of pediatric and adult age.
  Variables 
Pediatric PTLD Controls P Available 
data (n)<18 yr <12 yr <18 yr <12 yr <18 yr <12 yr
  age (Sd) in years 4.4 (4.6) - 44.3 (16.6) - - - 250
  Gender male (%) 56 (50.5) 52 (52.5) 17 (53.1) 21 (47.7) .843 .362 143
  Time to pTld development 
  (Sd) in months 29.5 (34.7) 26.8 (33.2) 25.5 (36.7) 35.0 (40.3) .547 .112 172
  early onset disease (%) 69 (50.4) 66 (53.7) 18 (51.4) 19 (41.3) .531 .104 172
  multiorgan involvement  
  (%)a 66 (54.5) 60 (55.6) 12 (46.2) 18 (46.2) .518 .206 147
  disseminated pTld (%)a 20 (23.8) 16 (21.6) 6 (26.1) 10 (30.3) .79 .233 107
  B cell type (%) 35 (89.7) 29 (87.9) 17 (100) 23 (100) .303 .111 56
  Morphology
     early lesion (plasmacytic 
     hyperplasia) 7 (5.6) 7 (6.5) 0 0
.09 .004 157
     polymorphic B cell 
     lymphoma 68 (54) 61 (56.5) 12 (38.7) 17 (37.8)
     monomorphic pTld 44 (34.9) 33 (30.6) 18 (58.1) 27 (60)
     Hodgkin lymphoma 7 (5.6) 7 (6.5) 1 (3.2) 1 (2.2)
  eBV status (%) 72 (82.8) 64 (81) 20 (83.3) 28 (87.5) .609 .301 111
  author defined remission 
  episode (%) 38 (82.6) 35 (83.3) 13 (81.3) 16 (80) .585 .502 62
  remission (%)a 74 (79.6) 67 (78.8) 20 (80) 27 (81.8) .604 .466 118
  polyclonal lesions - vs.   
  monoclonal (%) 18 (48.6) 13 (41.9) 11 (73.3) 16 (76.2) .093 .023 52
  death due to pTld (% of 
  mortality) 25 (73.5) 24 (25.8) 10 (71.4) 11 (28.2) .765 .476 48
abased on the defined criteria; 
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tation). According to the new categorization, PTLD 
lesions developing in pediatric liver recipients were 
more likely to be polyclonal (56% vs. 23%; P=0.035) 
and polymorphic (58% vs. 40%; P=.045). However, 
survival analysis showed no significant outcome differ-
ence (P=.667; Figure 3). Finally data was reanalyzed 
excluding adult patients. Survival analysis showed that 
T-cell type PTLD lesions (P=.002) as well as multior-
gan involvement (P=.048; Figure 4) were significantly 
associated with inferior outcome. 
Figure 1. Survival curves of liver transplant recipients developing 
pTld by age at transplantation.
DISCuSSIOn
The practice of transplantation witnessed significant 
improvement when new immunosuppressive agents 
were introduced. However, using the newly developed 
potent immunosuppressants was associated with the 
development of post-transplant malignancies including 
PTLD, which immensely threatens the lives of organ 
transplant recipients. The rate of PTLD developing in 
liver recipients is considered comparable to renal graft 
recipients and lower than most other organ transplant 
patients. In the pediatric setting, the overall incidence of 
PTLD has been reportedly up to 1.2% of all recipients 
or 298/100 000 posttransplantation years of follow-
up.34,55 This might mean that our study population 
can be considered representative of over 18 000 pedi-
Table 2. Comparison of frequencies of organ involvements by 
pTld in the study patient groups.
  Involved organs Pediatric PTLDa Controls P
  Orbit 2 (1.5) 0 .695
  Skin 2 (1.6) 0 .68
  Stomachb 11 (10) 0 .035
  Genitalia 1 (1) 1 (4) .312
  CnS  6 (4) 1 (4) .696
  Spleen 13 (10) 2 (8) .557
  renal 
  involvement 3 (2) 1 (4) .524
  respiratory 
  system 16 (12.4) 5 (19.2) .353
  liver 32 (24) 9 (35) .329
  Bone marrow 8 (6.2) 3 (11.5) .396
  Small intestine 23 (19) 4 (16) .503
  Colon 4(3) 2(8) .278
apediatric liver recipients developing pTld; bage cut off at 12 years;
Figure 2. Survival curves of liver recipients of pediatric or adult 
age after censoring events occurring within the first 4 months.
Figure 3. Survival curves of liver recipients whose pTld lesions 
developed when they were at pediatric or adult age.
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atric liver transplant population; or over 71 000 years 
of posttransplant follow up. This shows the magnitude 
of the findings of the present article. Moreover, when 
considering the frequency of liver transplantation in 
children, our study population will more prominently 
come into view. 
In this study, we tried to eliminate the limitation 
of data existing in individual and multicenter reports, 
while trying to find and accumulate all the retrievable 
existing data available to form a database. Thus, we 
conducted a very through and comprehensive search 
for all cases of pediatric liver transplants that developed 
PTLD. We believe that our study represents the larg-
est investigation of  liver transplant pediatric PTLD 
patients.
Epstein Barr-virus (EBV) infection has been pro-
posed as a significant risk factor in inducing PTLD es-
pecially in the pediatric transplant setting. Guthery et 
al, proposed that younger age is associated with EBV-
associated PTLD development in pediatric liver trans-
plantation, although they did not exclude detection bias 
as an explanation for their observation. 56 The proposed 
rationale behind this finding is that the seronegativity 
of children places them at a higher risk of seroconver-
sion and PTLD as a consequence. Controversial obser-
vations have also been reported where older children 
were more likely to develop EBV-associated PTLD. 57 
In this study, however, we found no association between 
EBV serology and younger age, although our observa-
tion was not able to show seroconversion. 
Previous studies have shown better PTLD out-
comes in younger children.57,58 Survival analysis of our 
study population, however, showed no outcome differ-
ence related to patient age. Nevertheless, a precise look 
at the survival curves shows an improvement in pedi-
atric patients. After a survival reanalysis after censor-
ing events occurring within the early months, we found 
that for patients who survive the first 4 post transplant 
months, pediatric PTLD patients have a superior out-
come compared to adults (>18 years).
Histopathological features of PTLD among pedi-
atric PTLD patients were of significantly more benign 
types. Moreover, reanalysis of data on lower age cut-off 
points showed a larger significant difference. This find-
ing is in concordance with our previous knowledge as 
well as our finding of better survival of pediatric PTLD 
patients compared to their adult counterparts, while 
it has been shown that polymorphic PTLD lesions in 
children respond better to antimalignancy therapies 
than monomophic ones.59 However, data on histo-
Figure 4. Survival curves of pediatric liver recipients developing 
pTld regarding their disease extent.
pathological disparities in PTLD lesions related to age 
is controversial. In renal graft recipients, Shapiro et al 
found no significant difference in the histopathology 
of PTLD lesions by age groups with both groups hav-
ing more monomorphic lesions.58 While Cacciarelli et 
al showed that 75% of lesions in pediatric PTLD liver 
recipients were early lesions. Polyclonal lesions were 
also more frequently seen in pediatric patients.11 This 
can also provide another explanation for the superior 
survival observed in pediatric PTLD patients.   
This study has several limitations. First, data for this 
study was accumulated from different published re-
ports whose approaches were not essentially consistent. 
For example, a report of any response to treatment was 
presented very dissimilarly in different studies, while 
in one study partial and complete remission were used 
to translate the results, while in another only “response 
to treatment” was used and in some others no specific 
terminology was employed. Thus,  we ought to invent 
new methods to standardize different data presenta-
tion types to be able to accumulate the existing data for 
analysis. 
In conclusion, this study showed that pediatric liver 
transplant recipients developing PTLD are more likely 
to develop lesions with more favorable histopathologi-
cal features. Except for the very early post-transplant 
period, they also have better survival compared to older 
liver transplant patients. Future prospective studies 
with larger patient population and more controlled con-
ditions are needed for confirming our findings.
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